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Table. Results and indications for percutaneous endovascular aortic aneurysm repair (PEVAR) utilizing superﬁcial femoral artery (SFA)
Patient MAIN LIMB Indication for SFA Complication
Follow-up CT
results
Time to
follow-up
(months)
Device
caliber
R (F)
Device
caliber
L (F)
1 R SFA L SFA Calciﬁed bilateral CFAs, morbid obesity None Patent R & L SFA 1 18 14
2 R SFA Calciﬁed bilateral CFAs None Patent R SFA 2 18
3 R SFA Morbid obesity, prior groin infections None Patent R SFA 1 16
4 L SFA High CPA bifurcation None Patent L SFA 8 14
5 L SFA Morbid obesity Suture
Positioning bleed
Patent L SFA 8 20
6 L SFA R SFA Morbid obesity SFA thrombus Patent R & L SFA 8 14 20
7 L SFA R SFA Tortuous iliac arteries None Patent R & L SFA 1 16 18
8 R SFA Signiﬁcant anterior wall thrombus of R CFA None Patent R SFA 12 14
9 R SFA Calciﬁed R CFA None Patent R SFA 13 14
10 L SFA Scarring/visible repair site of L CFA None Patent L SFA 12 18
CFA, Common femoral artery.
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Mirnal Chaudhary, MD, Jayne Miely, BS, John Matsuura, MD. Wright
State University, Dayton, Ohio
Objectives: The Magellan Robot catheter (Hansen Medical, Moun-
tain View, Calif) recently received clearance by the Food and Drug Admin-
istration for use on peripheral vessels. Our institution acquired the system in
January 2014. We report our institution’s initial experience with the Magel-
lan system.
Methods: We retrospectively reviewed the records for all patients
who underwent Magellan-assisted endovascular procedures between
January 28, 2014, and April 26, 2014. Prior to the ﬁrst procedure, the
attending surgeon and staff underwent simulator and model training
and certiﬁcation for the Magellan system. Patient demographics, comor-
bidities, and operative statistics were recorded for analysis in accordance
with IRB guidelines.
Results: A total of 14 patients (64% male) underwent 15 Magel-
lan-assisted therapies. The average age of our patients was 68 years.
Four patients had undergone previous open or endovascular procedures
on the treated extremity. Eight procedures involved atherosclerotic
occlusive disease of the legs, 3 aortic aneurysm repairs, 2 visceral steno-
ses, 1 subclavian artery occlusion, and 1 right innominate vein occlu-
sion. One case was aborted due to small iliac and femoral artery
access. Two cases were unsuccessful due to failure to cross a venous
chronic total occlusion and inability to advance the robotic sheath
into the innominate artery. Operative statistics included an average
blood loss of 125 6 114 mL, 57 6 42 mL contrast use, and 30 6
14 minutes of ﬂuoroscopy time, with an average radiation exposure
of 4866 6 6639 mGy.
Conclusions: The overall success rate for the Magellan system was
87%. There was a deﬁnite learning curve, as evidenced by our longer ﬂuo-
roscopy times. However, the ﬂexibility of the leader catheter and ability
to turn 180o made it possible to treat visceral arteries from the groin. We
also found an advantage with the robotic catheter in crossing the iliac bifur-
cation even in patients with acute angulation or prior stenting. As more cen-
ters acquire the Magellan system, we feel participation in the ROVER
robotic catheter registry will play a vital role in better deﬁning the proper
use of this new technology.
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Access Site Complications Are Commonly Found on Femoral Artery
Duplex Ultrasound and Associated With Age and Manual Pressure
Loren L. Masterson, MD, Todd Corby Mounir Haurani, MD, Lianbo
Yu, PhD, Jean Starr, MD. Vascular Diseases and Surgery, The Ohio State
University, Columbus, Ohio
Objectives: A duplex ultrasound study (DUS) is often the ﬁrst test to
evaluate the femoral vessels for complication after percutaneous femoral ac-
cess performed for cardiac and peripheral vascular (PV) diagnostic and inter-
ventional procedures. This retrospective study examined all patients over a
2-year period who underwent a DUS for a suspected access site complica-
tion after femoral access at our institution to try to deﬁne risk factors for
developing a complication.
Methods: The hospital peripheral vascular laboratory database was
reviewed, and all patients who underwent femoral DUS from January2010 to December 2011 were identiﬁed. Patients were excluded if they
did not have a femoral access procedure performed at our institution for
vascular or cardiac diagnostic/interventional purposes #1 month prior to
the DUS. Hospital records were reviewed, and demographics, procedural
details, and complications were recorded. Completion angiograms were
graded by a single investigator for location of puncture, femoral disease,
and size of the femoral artery.
Results: A total of 18,167 cardiac and PV procedures were performed
during the study period. A total of 222 patients had a DUS and were
divided into those with an access site complication (group A, 103 patients
[46.4%]) and those without (group B, 119 patients [53.6%]). Gender and
body mass index were similar between the groups; however, the group A
patients were signiﬁcantly older than the group B patients (62.4 vs 56.9
years; P ¼ .003). The most common complications identiﬁed on DUS
were hematoma (n ¼ 55 [53.4%]) and pseudoaneurysm (n ¼ 33
[32.0%]). A closure device was more commonly used in group B patients
(71 vs 49 patients; P ¼ .007). No single femoral anatomic feature on
completion angiogram was more commonly associated with sustaining a
complication.
Conclusions: DUS, performed for evaluation of the femoral access
site after cardiac or PV procedures, has a high yield for complications. He-
matoma is the most common complication, followed by pseudoaneurysm.
Older age and manual pressure for closure were associated with access site
complication.
Author Disclosures: L. L. Masterson: None; T. Corby: None; M.
Haurani: None; L. Yu: None; J. Starr: None.
Stent Fractures and Restenosis Rates Following Carotid Artery
Stenting
Mohammad Sarhan, MD, Sherry L. Cavanagh, MD, Robert G.
Molnar, MD. Vascular Surgery, Michigan Vascular Center/Michigan
State University/McLaren Region Medical Center, Flint, Mich
Objectives: Carotid artery stenting (CAS) is being performed more
frequently for carotid occlusive disease and has been approved for use in
high-risk patients. There have been reports of carotid stent fractures, but
prospective data are limited. To better understand the incidence of CAS
fracture and risk of restenosis, we prospectively evaluated CAS patients for
fracture and restenosis.
Methods: Patients who underwent CAS between January 2002 and
January 2012 were prospectively evaluated for stent fractures by anteropos-
terior and lateral cervical x-ray imaging and for restenosis by duplex ultra-
sound imaging at 1 month, 6 months, and 1 year. The x-ray images were
independently reviewed by two surgeons and two radiologists for the ﬁrst
part of the study and by three independent surgeons in the later part to
assess for stent fractures. The fracture incidence was then calculated as a per-
centage of the study population. Carotid duplex results were correlated to
those with and without stent fractures.
Results: During the study period, 400 stents were placed. A total of
143 patients, with 163 stents, agreed to participate in the study. Fractures
were found in 11 of the 163 stents (6%). Fractures were only counted if
there was unanimous agreement by the reviewers, and possible fractures
were not considered. Of the 11 with stent fractures identiﬁed, one patient
(9%) had a restenosis of 50% to 60% at 6 months and 1 year. Restenosis
occurred in eight of 152 (5%) without stent fractures, two of them were se-
vere (>80%) and the remaining six were <50%.
